



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/825,629
Applicant : Don J. DIAMOND
Filed : April 16, 2004
TC/A.U. : 1648
Examiner : To Be Assigned

Docket No. : 1954-394
Customer No. : 06449
Confirmation No. : 8000
Title : HUMAN CYTOMEGALOVIRUS ANTIGENS EXPRESSED
IN MVA AND METHODS OF USE


INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450


Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith an International Search Report and Written Opinion mailed September 1, 2004 in connection with corresponding International Application No. PCT/US04/11891 and other information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449.

Respectfully submitted,

By 
Martha Cassidy
Attorney for Applicants
Registration No. 44,066
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

Enclosure(s):
International Search Report
PTO-1449 Forms
References
1954-394.ids.wpd



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		10/825,629
				Filing Date		April 16, 2004
				First Named Inventor		Don J. DIAMOND
				Group Art Unit		1648
				Examiner Name		To Be Assigned
Sheet	1	of	13	Attorney Docket Number		1954-394

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind code ² (if known)		
	A1	US 5,591,439		Plotkin et al.	01/07/1997
	A2	US 6,074,645		Diamond et al.	06/13/2000
	A3	US 6,133,433		Pande et al.	10/17/2000
	A4	US 6,156,317		Diamond et al.	12/05/2000
	A5	US 6,242,567	B1	Pande et al.	06/05/2001
	A6	US 6,251,399	B1	Diamond et al.	06/26/2001
	A7	US 6,544,521	B2	Diamond	04/08/2003
	A8	US 6,562,345	B1	Diamond et al.	05/13/2003
	A9	US 6,632,435	B1	Diamond	10/14/2003
	A10	US 6,726,910	B2	Diamond	04/27/2004
	A11	US 6,727,093	B2	Diamond	04/27/2004
	A12	US 6,733,973	B2	Diamond	05/11/2004
	A13	US 6,843,992	B2	Diamond	01/18/2005

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document
		Office ³	Number ⁴	Kind ⁵ Code (if known)	
	WO	02/34769		A2	City of Hope

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	2	of	13	Attorney Docket Number	1954-394
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	B1	ADLER et al., "A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)." J. of Infect. Dis. 180:843-846, 1999.			
	B2	AGUADO et al., "Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3." Antimicrob. Agents Chemother. 39:1643-1645, 1995.			
	B3	ALLEN et al., "Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes From Rhesus Macaques Vaccinated With a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen." J. Immunol. 164:4968-4978, 2000.			
	B4	ALP et al., "Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein." J. Virol. 65:4812-4820, 1991.			
	B5	AMARA et al., "Different Patterns of Immune Responses but Similar Control of a Simian- Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines." J. Virol. 76:7625-7631, 2002.			
	B6	AMARA et al., "Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine." Science 292:69-74, 2001.			
	B7	BANKS et al., "A Major Neutralizing Domain Maps Within the Carboxyl-Terminal Half of the Cleaved Cytomegalovirus B Glycoprotein." J. Gen. Virol. 70:979-985, 1989.			
	B8	BASGOZ et al., "The Amino Terminus of Human Cytomegalovirus Glycoprotein B Contains Epitopes That Vary Among Strains." J. of Gen. Virol. 73:983-988, 1992.			
	B9	BENDER et al., "Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza." J. Virol. 70:6418-6424, 1996.			
	B10	BERENCSI et al., "A Canarypox Vector-Expressing Cytomegalovirus (CMV) Phosphoprotein 65 Induces Long-lasting Cytotoxic T Cell Responses in Human CMV-Seronegative Subjects." J. Infect. Dis. 183:1171-1179, 2001.			
	B11	BERENCSI et al., "Murine Cytotoxic T Cell Response Specific for Human Cytomegalovirus Glycoprotein B (gB) Induced by Adenovirus and Vaccinia Virus Recombinants Expressing gB." J. Gen. Virol. 74(pt 11):2507-2512, 1993.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	3	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B12	BERNSTEIN et al., "Effect of Previous or Simultaneous Immunization With Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine Plus MF59 in Healthy CMV-Seronegative Adults." J. Infect. Dis. 185:686-690, 2002.	
	B13	BENMOHAMED et al., "Intranasal Administration of a Synthetic Lipopeptide Without Adjuvant Induces Systemic Immune Responses." Immunology 106:113-121, 2002.	
	B14	BLANCHARD et al., "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: implications for use as a human vaccine." J. Gen. Virol. 79(Pt 5):1159-1167, 1998.	
	B15	BOPPANA et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells." Virology. 222:293-296, 1996.	
	B16	BORYSIEWICZ et al., "Human Cytomegalovirus-Specific Cytotoxic T Cells." J. Exp. Med. 168:919-931, 1988.	
	B17	BRITT et al., "Formulation of an Immunogenic Human Cytomegalovirus Vaccine: Responses in Mice." J. Infect Dis. 171:18-25, 1995.	
	B18	BRITT et al., "Cell Surface Expression of Human Cytomegalovirus (HCMV) gp55-116 (gB): Use of HCMV-Recombinant Vaccinia Virus-Infected Cells in Analysis of the Human Neutralizing Antibody Response." J. Virol. 64:1079-1085, 1990.	
	B19	CARROLL et al., "Host Range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus: Propagation and Generation of Recombinant Viruses in a Nonhuman Mammalian Cell Line." Virology 238:198-211, 1997.	
	B20	CARROLL et al., "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) As An Effective Recombinant Vector: A Murine Tumor Model." Vaccine 15 (4):387-394, 1997.	
	B21	CHEE et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169." Current Topics in Microbiol. Immunol. 154:126-169, 1990.	
	B22	CRANAGE et al., "Identification of the Human Cytomegalovirus Glycoprotein B Gene and induction of Neutralizing Antibodies Via Its Expression in Recombinant Vaccinia Virus." EMBO J. 5(11):3057-3063, 1986.	
	B23	D'AMARO et al., "A Computer Program for Predicting Possible Cytotoxic T Lymphocyte Epitopes Based on HLA Class I Peptide-Binding Motifs." Human Immunol. 43:13-18, 1995.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	4	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B24	DÉGANO et al., "Gene Gun Intradermal DNA Immunization Followed By Boosting With Modified Vaccinia Virus Ankara: Enhanced CD8 ⁺ T Cell Immunogenicity and Protective Efficacy in the Influenza and Malaria Models." Vaccine 18:623-632, 2000.	
	B25	DELOGU et al., "DNA Vaccine Combinations Expressing Either Tissue Plasminogen Activator Signal Sequence Fusion Proteins or Ubiquitin-Conjugated antigens Induce Sustained Protective Immunity in a Mouse Model of pulmonary Tuberculosis." Infect. and Immunity 70:292-302, 2002.	
	B26	DELOGU et al., "DNA Vaccination against Tuberculosis: expression of a ubiquitin- conjugated tuberculosis protein enhances antimycobacterial immunity." Infect. Immunity 68.6:3097-3102, 2000.	
	B27	DIAMOND et al., "Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection." Blood 90(5):1751-1767, 1997.	
	B28	EINSELE et al., "Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide." Cytotherapy 4:49-54, 2002.	
	B29	ELKINGTON et al., "Ex Vivo Profiling of CD8 ⁺ -T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers." J. Virol. 77(9):5226-5240, 2003.	
	B30	ENDRESZ et al., "Induction of Human Cytomegalovirus (HCMV)-Glycoprotein B (gB)-Specific Neutralizing Antibody and Phosphoprotein 65 (pp65)-Specific Cytotoxic T Lymphocyte Responses By Naked DNA Immunization." Vaccine 17:50-58, 1999.	
	B31	ENDRESZ et al., "Optimization of DNA Immunization Against Human Cytomegalovirus." Vaccine 19:3972-3980, 2001.	
	B32	FIRAT et al., "Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/ HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice." Int. Immunol. 14:925-934, 2002.	
	B33	FU et al., "Induction of MHC Class I-Restricted CTL Response by DNA Immunization with Ubiquitin-Influenza Virus Nucleoprotein Fusion Antigens." Vaccine 16(18):1711-1717, 1998.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	5	of	13	Attorney Docket Number	1954-394
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	B34	GALLEZ-HAWKINS et al., "Kinase-Deficient CMVpp65 Triggers a CMVpp65 Specific T-Cell Immune Response in HLA-A*0201.Kb Transgenic Mice after DNA Immunization." Scand. J. Immunol. 55:592-598, 2002.			
	B35	GALLEZ-HAWKINS et al., "Use of Transgenic HLA A*0201/Kb and HHD II Mice to Evaluate Frequency of Cytomegalovirus IE1-Derived Ppeptide Usage in Eliciting Human CD8 Cytokine Response." J. Virol. 77:4457-4462, 2003.			
	B36	GILBERT et al., "Selective Interference with Class I Major Histocompatibility Complex Presentation of the Major Immediate-Early Protein Following Infection with Human Cytomegalovirus." J. Virol. 67:3461-3469, 1993.			
	B37	GILLESPIE et al., "Functional heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8(+) T Lymphocytes in Healthy Seropositive Donors." J. Virol. 74:8140-8150, 2000.			
	B38	GONCZOL et al., "Progress in Vaccine Development for Prevention of Human Cytomegalovirus Infection." Curr. Top. Microbiol. Immunol. 154:255-274, 1990.			
	B39	GONCZOL et al., "High Expression of Human Cytomegalovirus (HCMV)-gB Protein in Cells Infected With a Vaccinia-gB Recombinant: The Importance of the gB Protein in HCMV Immunity. Vaccine 9:631-637, 1991.			
	B40	GONCZOL et al., "Preclinical Evaluation of an ALVAC (Canarypox)-Human Cytomegalovirus Glycoprotein B Vaccine Candidate. Vaccine 13(12):1080-1085, 1995.			
	B41	GONCZOL et al., "Isolated gA/gB Glycoprotein Complex of Human Cytomegalovirus Envelope Induces Humoral and Cellular Immune Responses in Human Volunteers." Vaccine 8:130-136, 1990.			
	B42	GONCZOL et al., "Development of a Cytomegalovirus Vaccine: Lessons From Recent Clinical Trials." Exp. Opin. Biol. Ther. 1(3):401-412, 2001.			
	B43	GRANT et al., "Rate of Antigen Degradation by the Ubiquitin-Proteasome Pathway Influences MHC Class I Presentation." J. Immunol. 155:3750-3758, 1995.			
	B44	GRIFFITHS, "Cytomegalovirus Therapy: Current Constraints and Future Opportunities", Curr. Opin. Infect. Dis. 14:765-768, 2001.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	6	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B45	GRIFFITHS, "The Treatment of Cytomegalovirus Infection." J. of Antimicrobial Chem. 49:243-253, 2002.	
	B46	GYULAI et al., "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1-Specific CTLs." J. Infect. Dis. 181:1537-1546, 2000.	
	B47	HAMEL et al., "Characterization of Antigen-Specific Repertoire Diversity Following in Vitro Restimulation by a Recombinant Adenovirus Expressing Human Cytomegalovirus pp65." Eur. J. Immunol. 33:760-768, 2003.	
	B48	HANKE et al., "Effective Induction of HIV-Specific CTL by Multi-epitope Using Gene Gun in a Combined Vaccination Regime." Vaccine 17:589-596, 1999.	
	B49	HANKE et al., "Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen." J. Virol. 73(9):7524-7532, 1999.	
	B50	HANKE et al., "Pre-clinical Development of a Multi-CTL Epitope-based DNA Prime MVA Boost Vaccine for AIDS." Immunol. Lett. 66:177-181, 1999.	
	B51	HANKE et al., "Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus ankara-Based Multi-CTL Eptiope Vaccine for Human Immunodeficiency Virus Type 1 in Mice." J. Gen. Virol. 79:83-90, 1998.	
	B52	HANKE et al., "Design and Construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya." Nat. Med. 6(9):951-955, 2000.	
	B53	HIRSCH et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara." J. Virol. 70(6):3741-3752, 1996.	
	B54	ISHIOKA et al., "Utilization of MHC Class I Transgenic Mice for Development of Minigene DNA Vaccines Encoding Multiple HLA-Restricted CTL Epitopes." J. Immunol. 162:3945-3925, 1999.	
	B55	KEEVER-TAYLOR et al., "Cytomegalovirus-Specific Cytolytic T-Cell Lines and Clones Generated Against Adenovirus-pp65-Infected Dendritic Cells." Biol. Blood Marrow Transplantation 7:247-256, 2001.	
	B56	KERN et al., "Target Structures of the CD8 ⁺ T Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited." J. Virol. 73(10):8179-8184, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	7	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B57	KHAN et al., "Comparative Analysis of CD8 ⁺ T Cell Responses Against Human Cytomegalovirus Proteins pp65 and Immediate Early 1 Shows Similarities in Precursor Frequency, Oligoclonality, and Phenotype." J. Infect. Dis. 185:1025-1034, 2002.	
	B58	KLEIHAUER et al., "Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells." Brit. J. Haematol. 113:231-239, 2001.	
	B59	KLEIN et al., "Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera." J Virol. 73:878-886, 1999.	
	B60	LACEY et al., "Relative Dominance of HLA-B*07 Restricted CD8 ⁺ T-Lymphocyte Immune Responses to Human Cytomegalovirus pp65 in Persons Sharing HLA-A*02 and HLA-B*07 Alleles." Hum. Immunol. 64:440-452, 2003.	
	B61	LANG et al., "High Frequency of Human Cytomegalovirus (HCMV)-Specific CD8 ⁺ T Cells Detected in a Healthy CMV-Seropositive Donor." Cell Mol. Life Sci. 59:1076-1080, 2002.	
	B62	LA ROSA et al., "Preclinical Development of an Adjuvant-Free Peptide Vaccine With Activity Against CMV pp65 in HLA Transgenic Mice." Blood 100(10):3681-3689, 2002.	
	B63	LEVY et al., "Using Ubiquitin to Follow the Metabolic Fate of a Protein." Proc. Natl. Acad. Sci. USA 93:4907-4912, 1996.	
	B64	LI et al., "Human Cytomegalovirus Matrix Protein pp150 is Efficiently Presented as One of Target Antigens for Cytotoxic T Lymphocyte Recognition." Chin. Med. J. (Engl.) 110:397-400, 1997.	
	B65	LIU et al., "Molecular Analysis of the Immune Response to Human Cytomegalovirus Glycoprotein B. I. Mapping of HLA-Restricted Helper T Cell Epitopes on gp93." J. Gen. Virol. 74:2207-2214, 1993.	
	B66	LIU et al., "Polynucleotide Viral Vaccines: codon optimization and ubiquitin conjugation enhances prophylactic and therapeutic efficacy." Vaccine 20:862-869, 2002.	
	B67	LONGMATE et al., "Population Coverage By HLA Class-I Restricted Cytotoxic T-Lymphocyte Epitopes." Immunogenetics 52:165-173, 2001.	
	B68	MARSHALL et al., "An Adenovirus Recombinant That Expresses the Human Cytomegalovirus Major Envelope Glycoprotein and Induces Neutralizing Antibodies." J. Infect. Dis. 162:1177-1181, 1990.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	8	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B69	MARSHALL et al., "Antibodies to Recombinant-Derived Glycoprotein B After Natural Human Cytomegalovirus Infection Correlate With Neutralizing Activity." J. Infect. Dis. 165:381-384, 1992.	
	B70	MARSHALL et al., "Antibodies to the Major Linear Neutralizing Domains of Cytomegalovirus Glycoprotein B Among Natural Seropositives and CMV Subunit Vaccine Recipients." Virol. Immunol. 13(3):329-341, 2000.	
	B71	MCCONKEY et al., "Enhanced T-Cell Immunogenicity of Plasmid DNA Vaccines Boosted by Recombinant Modified Vaccinia Virus Ankara in Humans." Nat.Med. 9(6):729-735, 2003.	
	B72	MCLAUGHLIN-TAYLOR et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8 ⁺ Virus-Specific Cytotoxic T Lymphocytes." J. Med. Virol. 43:103-110, 1994.	
	B73	MEN et al., "Immunization of Rhesus Monkeys With a Recombinant of Modified Vaccinia Virus Ankara Expressing a Truncated Envelope Glycoprotein of Dengue Type 2 Virus Induced Resistance to Dengue Type 2 Virus Challenge." Vaccine 18:3113-3122, 2000.	
	B74	MEYER et al., "Glycoprotein gp116 of Human Cytomegalovirus Contains Epitopes for Strain-Common and Strain-Specific Antibodies." J. Gen. Virol. 73:2375-2383, 1992.	
	B75	MORELLO et al., "Development of a Vaccine Against Murine Cytomegalovirus (MCMV), Consisting of Plasmid DNA and Formalin-Inactivated MCMV, That Provides Long-Term, Complete Protection Against Viral Replication." J. Virol. 76(10):4822-4835, 2002.	
	B76	MORELLO et al., "Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)." J. Virol. 74:3696-3708, 2000.	
	B77	MOSS et al., "Host Range Restricted, Non-Replicating Vaccinia Virus Vectors As Vaccine Candidates." Adv. Exp. Med. Biol. 397:7-13, 1996.	
	B78	NIETHAMMER et al., "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by An Autologous Oral DNA Vaccine Against Murine Melanoma." Cancer Research 61:6178-6184, 2001.	
	B79	PANDE et al., Human Cytomegalovirus Strain Towne pp28 Gene: Sequence Comparison to pp28 of HCMV AD169 and Stable Expression in Chinese Hamster Ovary Cells." Virology 184:762-767, 1991.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	9	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B80	PANDE et al., "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in Escherichia Coli." Virology 182:220-228, 1991.	
	B81	PANDE et al., "Direct DNA Immunization of Mice With Plasmid DNA Encoding the Tegument Protein pp65 (ppUL83) of Human Cytomegalovirus Induces High Levels of Circulating Antibody to the Encoded Protein." Scand. J. Infect. Dis. Suppl. 99:117-120, 1995.	
	B82	PANDE et al., "Structural Analysis of a 64-Kda Major Structural Protein of Human Cytomegalovirus (Towne): Identification of a Phosphorylation Site and Comparison to pp65 of HCMV (AD 169)." Virology 178:6-14, 1990.	
	B83	PAPANICOLAOU et al., "Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele." Blood 102:2498-2505, 2003.	
	B84	PASS et al., "A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant." J. Infect. Dis. 180:970-975, 1999.	
	B85	PROD'HOMME et al., "Modulation of HLA-A*0201-Restricted T Cell Responses By Natural Polymorphism in the HE1 ₃₁₅₋₃₂₄ Epitope of Human Cytomegalovirus." J. Immunol. 170:2030-2036, 2003.	
	B86	RAMIREZ et al., "Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison With the Western Reserve Strain and Advantages as a Vaccine." J. Virol. 74(2):923-933, 2000.	
	B87	RAMIREZ et al., "Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent Under Conditions of Preexisting Immunity to the Vector." J. Virol. 74(16):7651-7655, 2000.	
	B88	RASMUSSEN et al., "Antibody Response to Human Cytomegalovirus Glycoproteins gB and gH After Natural Infection in Humans." J. Infect. Dis. 164:835-842, 1991.	
	B89	RETIERE et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells With Stable Expression of pp65 or IE1 Proteins: a Tool to Study the Fine Specificity of the Antiviral Response." J. Virol. 74(9):3948-3952, 2000.	
	B90	REVELLO et al., "Human Cytomegalovirus Immediate-Early Messenger RNA in Blood of Pregnant Women With Primary Infection and of Congenitally Infected Newborns." J. Infect. Dis. 184:1078-1081, 2001.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	10	of	13	Attorney Docket Number	1954-394
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	B91	RIDDELL et al., "Class I MHC-Restricted cytotoxic T Lymphocyte Recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression." J. Immunol. 146:2795-2804, 1991.			
	B92	ROCK et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides." Annu. Rev. Immunol. 17:739-779, 1999.			
	B93	RODRIGUEZ et al., "DNA Immunization: Ubiquitination of a Viral Protein Enhances Cytotoxic T-Lymphocyte Induction and Antiviral Protection But Abrogates Antibody Induction." J. Virol. 71(11):8497-8503, 1997.			
	B94	RODRIGUEZ et al., "DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination." J. Virol. 72:5174-5181, 1998.			
	B95	ROTHER et al., "An Antigen Fragment Encompassing the AD2 Domains of Glycoprotein B From Two Different Strains is Sufficient for Differentiation of Primary Vs. Recurrent Human Cytomegalovirus Infection by ELISA." J. Med. Virol. 65:719-729, 2001.			
	B96	ROWELL et al., "Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells." J. Immunol. 155:1818-1828, 1995.			
	B97	ROY et al., "Sequence Variation Within Neutralizing Epitopes of the Envelope Glycoprotein B of Human Cytomegalovirus: Comparison of Isolates From Renal Transplant Recipients and AIDS Patient." J. Gen. Virol. 74:2499-2505, 1993.			
	B98	RUFF et al., "The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway." J. Biol. Chem. 272:8671-8678, 1997.			
	B99	SCHIPPER et al., "Minimal Phenotype Panels; A method for achieving maximum population coverage with a minimum of HLA antigens." Human Immunology 51:95-98, 1996.			
	B100	SETH et al., "Recombinant Modified Vaccinia Virus Ankara-Simian Immunodeficiency Virus Gag-Pol Elicits Cytotoxic T-Lymphocytes in Rhesus Monkeys Detected by a Major Histocompatibility Complex Class I/Peptide Tetramer." Proc. Natl. Acad. Sci. USA 95:10112-10116, 1998.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	11	of	13	Attorney Docket Number	1954-394
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	B101	SETH et al., "Immunization With a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated With Reduction of Viremia After SIV Challenge." J. Virol. 74(6):2502-2509, 2000.			
	B102	SIJTS et al., "The Role of the Ubiquitin- Proteasome Pathway in MHC Class I Antigen Processing: Implications for Vaccine Design." Curr. Mol. Med. 1:665-676, 2001.			
	B103	SOLACHE et al., "Identification of Three HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in the Cytomegalovirus Protein pp65 That Are Conserved Between Eight Strains of the Virus ¹ ." J. Immunol. 163:5512-5518, 1999.			
	B104	SPAETE et al., "Human Cytomegalovirus Strain Towne Glycoprotein B Is Processed by Proteolytic Cleavage." Virology 167:207-225, 1988.			
	B105	SPAETE et al., "Human Cytomegalovirus Structural Proteins." J. Gen. Virol. 75:3287-3308, 1994.			
	B106	SPAETE, "A Recombinant Subunit Vaccine Approach to HCMV Vaccine Development." Transplantation Proceedings 23(3)(3):90-96, 1991.			
	B107	STITTELAAR et al., "Safety of Modified Vaccinia Virus Ankara (MVA) in Immune-Suppressed Macaques." Vaccine 19:3700-3709, 2001.			
	B108	SUTTER et al., "A Recombinant Vector Derived From the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus." Vaccine 12(11):1032-1040, 1994.			
	B109	SUTTER et al., "Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant." J. Virol., 68:4109-4116, 1994.			
	B110	SUZUKI et al., "Degradation Signals in the Lysine-Asparagine Sequence Space." EMBO J. 18(21):6017-6026, 1999.			
	B111	TOBERY et al., "Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses in Vivo After Immunization." J. Exp. Med. 185(5):909-920, 1997.			
	B112	TOBERY et al., "Cutting Edge: Induction of Enhanced CTL-Dependent Protective Immunity in Vivo by N-End Rule Targeting of a Model Tumor Antigen." J. Immunol. 162:639-642, 1999.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	12	of	13	Attorney Docket Number	1954-394
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	B113	TOWNSEND et al., "Defective Presentation to Class I-Restricted Cytotoxic T Lymphocytes in Vaccinia-Infected Cells Is Overcome by Enhanced Degradation of Antigen." J. Exp. Med. 168:1211-1224, 1988.			
	B114	URBAN et al., "Glycoprotein H of Human Cytomegalovirus is a Major Antigen for the Neutralizing Humoral Immune Response." J. Gen Virol. 77:1537-1547, 1996.			
	B115	URBAN et al., "The Dominant Linear Neutralizing Antibody-Binding Site of Glycoprotein gp86 of Human Cytomegalovirus is Strain Specific." J. Virol. 66(3):1303-1311, 1992.			
	B116	UTZ et al., "Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus." J Virol. 63:1995-2001, 1989.			
	B117	VARSHAVSKY et al., "The Ubiquitin System and the N-End Rule Pathway." Biol. Chem. 381:779-789, 2000.			
	B118	VARSHAVSKY, "The N-End Rule: Functions, Mysteries, Uses." Proc. Natl. Acad. Sci. USA 93:12142-12149, 1996.			
	B119	VAZ-SANTIAGO et al., "Ex Vivo Stimulation and Expansion of Both CD4 ⁺ and CD8 ⁺ T Cells From Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65." J. Virol. 75(17):7840-7847, 2001.			
	B120	VELDERS et al., "Defined Flanking Spacers and Enhanced Proteolysis is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine." J. Immunol. 166:5366-5373, 2001.			
	B121	VIDALIN, et al., "Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination." DNA Cell. Biol. 18:611-621, 1999.			
	B122	VILLANUEVA et al., "Efficiency of MHC class I Antigen Processing: a Quantitative Analysis." Immunity 1:479-489, 1994.			
	B123	WELLS et al., "Structural and Immunological Characterization of Human Cytomegalovirus gp55-116 (gB) Expressed in Insect Cells." J. Gen. Virol. 71:873-880, 1990.			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/825,629
				Filing Date	April 16, 2004
				First Named Inventor	Don J. DIAMOND
				Group Art Unit	1648
				Examiner Name	To Be Assigned
Sheet	13	of	13	Attorney Docket Number	1954-394

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	B124	WILLS et al., "The Human Cytotoxic T-Lymphocyte (CTL) Response to Cytomegalovirus Is Dominated by Structural Protein pp65: Frequency, Specificity, and T-Cell Receptor Usage of pp65-Specific CTL." J. Virol. 70(11):7569-7579, 1996.	
	B125	WOLF et al., "How MHC Class II Molecules Acquire Peptide Cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell Dev. Biol. 11:267-306, 1995.	
	B126	WU et al., "Deoxyribonucleic Acid Vaccines Encoding Antigens with Rapid Proteasome-Dependent Degradation are Highly Efficient Inducers of Cytolytic T Lymphocytes." J. Immunol. 159:6037-6043, 1997.	
	B127	WU et al., "Engineering an Intracellular Pathway for Major Histocompatibility Complex Class II Presentation of Antigens." Proc. Natl. Acad. Sci. USA 92:11671-11675, 1995.	
	B128	WYATT et al., "Priming and Boosting Immunity to Respiratory Syncytial Virus by Recombinant Replication-Defective Vaccinia Virus MVA." Vaccine 18:392-397, 2000.	
	B129	WYATT et al., "Development of a Replication-Deficient Recombinant Vaccinia Virus Vaccine Effective Against Parainfluenza Virus 3 Infection in an Animal Model." Vaccine 14(15):1451-1458, 1996.	
	B130	XIANG et al., "An Autologous Oral DNA Vaccine Protects Against Murine Melanoma." Proc. Natl. Acad. Sci. USA 97(10):5492-5497, 2000.	
	B131	YAO et al., "Site-Directed Mutation in a Conserved Kinase Domain of Human Cytomegalovirus With Preservation of Cytotoxic T Lymphocyte Targeting." Vaccine 19:1628-1635, 2001.	
	B132	YE et al., "Strong CD8 T-Cell Responses following Coimmunization with Plasmids Expressing the Dominant pp89 and Subdominant M84 Antigens of Murine Cytomegalovirus Correlate with Long-Term Protection against Subsequent Viral Challenge." J Virol. 76:5, 2100-2112, 2002.	
	B133	ZAIA et al., "Status of Cytomegalovirus Prevention and Treatment in 2000." In <u>Hematology 2000</u> pp 339-355.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.